Taltobulin trifluoroacetate (HTI-286 trifluoroacetate) (Synonyms: HTI-286 trifluoroacetate; SPA-110 trifluoroacetate) |
Katalog-Nr.GC34135 |
Taltobulin-Trifluoracetat (HTI-286-Trifluoracetat) (HTI-286-Trifluoracetat), ein synthetisches Analogon des Tripeptids Hemiasterlin, ist ein wirksames Antimikrotubuli-Mittel, das die P-Glykoprotein-vermittelte Resistenz in vitro und in vivo umgeht. Taltobulintrifluoracetat (HTI-286-Trifluoracetat) hemmt die Polymerisation von gereinigtem Tubulin, unterbricht die Organisation der Mikrotubuli in Zellen und induziert einen mitotischen Stillstand sowie Apoptose.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 228266-41-9
Sample solution is provided at 25 µL, 10mM.
Taltobulin trifluoroacetate (HTI-286; SPA-110) is an analogue of Hemiasterlin; potent tubulin inhibitor; ADCs cytotoxin.IC50 value:Target: tubulinin vitro: HTI-286 significantly inhibited proliferation of all three hepatic tumor cell lines (mean IC50 = 2 nmol/L +/- 1 nmol/L) in vitro. Interestingly, no decrease in viable primary human hepatocytes (PHH) was detected under HTI-286 exposure [1]. In all cell lines tested, HTI-286 was a potent inhibitor of proliferation and induced marked increases in apoptosis. Despite similar transcriptomic changes regarding cell death and cell cycle regulating genes after exposure to HTI-286 or docetaxel, array analysis revealed distinct molecular signatures for both compounds [2].in vivo: Intravenous administration of HTI-286 significantly inhibited tumor growth in vivo (rat allograft model) [1]. HTI-286 significantly inhibited growth of PC-3 and LNCaP xenografts and retained potency in PC-3dR tumors. Simultaneous castration plus HTI-286 therapy was superior to sequential treatment in the LNCaP model [2].
[1]. Vashist YK, et al. Inhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin. World J Gastroenterol. 2006 Nov 14;12(42):6771-8. [2]. Hadaschik BA, et al. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin. Int J Cancer. 2008 May 15;122(10):2368-76.
Average Rating: 5
(Based on Reviews and 26 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *